AzTrials
AzTrials

Overweight, Obesity and Other HyperalimentationTHRIVENCT03478345

Taking Action to Thrive - A Healthy Lifestyle Intervention Pilot Study

A study testing endocrine disruptor chemical reduction intervention in people with Overweight, Obesity and Other Hyperalimentation, run by George Washington University at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

There have been some preliminary studies, primarily in animals, that suggest that exposure to some of the chemicals in our everyday environment, such as the chemicals found in plastics, may cause weight gain. Read more about this study

Who is it for?
Ages 18 to 35 years, women onlyHealthy volunteers can take part
What is being tested?
endocrine disruptor chemical reduction intervention
Could I receive a placebo?
No, everyone receives an active treatment
How many people
13 participants
Where
1 siteUnited States
Study dates
13 Mar 2018to 31 Dec 2018
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 35 years
  • Women only
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • female
  • BMI >25 kg/m2
  • willingness to participate in the 4-week long study
  • English speaking
  • capable of giving informed consent.

Who cannot join

  • males
  • current smoker, or having quit smoking within the past 6 months
  • currently or recently (past 6 months) pregnant or lactating, or planning to become pregnant in the next year
  • engaging in >150 minutes exercise/week
  • weight loss of ≥5 pounds over the past 6 months
  • post-menopausal
Show all 10Show fewer
  • pre-existing chronic diseases
  • use of medications known to alter body composition such as hormone replacements, oral contraceptives, and steroids
  • homeless persons, or individuals who have active drug/alcohol dependence or abuse history
  • Non-English speaking

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Milken Institute School of Public Health, George Washington University

    Washington D.C., District of Columbia, 20052

Other trials in United States

About this study

There have been some preliminary studies, primarily in animals, that suggest that exposure to some of the chemicals in our everyday environment, such as the chemicals found in plastics, may cause weight gain. It is not clear whether this also happens in humans, or whether decreasing exposure to these chemicals can improve success with weight loss when people adopt healthy lifestyle changes.

The THRIVE Study is a 4-week group healthy lifestyle education program that is designed to determine whether:

  • changes in dietary habits and the types of personal care products used can decrease a person's exposure to chemicals in our environment that have been suggested to cause weight gain
  • whether any measurable changes in body composition (fat tissue vs. lean tissue) can be seen as a result of participating in the healthy lifestyle program.
Read the detailed description

Emerging evidence from in vitro and animal models suggests that exposure to endocrine disrupting chemicals (EDC), or industrial chemicals that alter hormonal action, may contribute to the development of obesity. Phthalates, a class of industrial chemicals commonly found in personal care products and food packaging, warrant study since they are widely detected in the general US population, including reproductive aged-women, and exposures during adulthood are associated with an increased risk of obesity. However, the majority of the evidence supporting this hypothesis to date has come from cross-sectional rather than prospective, longitudinal data. Thus, a causal relationship between EDC exposure and the development of obesity has not been conclusively established.

Currently, 60.3% (95% CI: 54.2-66.0) of younger adult Americans (aged 20 - 39) are thought to be overweight or obese (BMI ≥25), which increases the risk of chronic diseases such as diabetes, cardiovascular disease and cancer. While excess calorie consumption and lack of physical activity are primary contributors to overweight and obesity, factors other than diet and physical activity may also contribute to alterations in energy balance over time. The general public is becoming increasingly concerned about the potential health risks associated with EDC exposures, including effects on body composition.

The THRIVE Study is designed to evaluate the effect of many different EDCs on body composition changes. The study will focus initially on exposures to the phthalate class of EDCs, but data will be collected in a way that will allow investigators to evaluate the effect of many different EDCs on body composition changes.

Phthalates are a class of high-production-volume industrial chemicals that are ubiquitously used in commerce. Most phthalates, such as DEHP, are used as plasticizers to impart flexibility in polyvinyl chloride (PVC) materials such as food packaging, flooring, and medical devices. In recent years, other phthalates, including diisononyl phthalate (DiNP), have been replacing DEHP in these applications due, in part, to legislation limiting the use of DEHP in certain applications such as children's toys. Phthalates can leach, migrate, or off-gas from products over time and enter the human body through the air we breathe, the food we eat, and the personal care products that we use on our bodies. Consequently, human exposure to phthalates is widespread.

Phthalates enter foods through contact with plastics (e.g. tubing, conveyor belts or plastic gloves made with PVC plastics) or recycled paper/cardboard food containers. Phthalates are more likely to leach into liquids and non-polar solvents such as fats and oils, and thus are most commonly found in foods high in animal fats such as dairy products and meat. Low-molecular weight phthalates, such as DEP, di-n-butyl phthalate (DnBP) and DiBP, are commonly found in fragranced personal care products such as perfumes, deodorants, soaps, shampoos, and other hair products (e.g. hair sprays, gels, mousses). They can also be found in time release medications and supplements. Intervention studies suggest that addressing sources of exposure can lower human exposure to phthalates. In a study of 20 individuals, a 3-day dietary intervention of "fresh foods" (no canned food or foods wrapped in plastic) resulted in an average reduction in DEHP metabolites of 53-56%. Similarly, a study of 100 Latina girls found that a 3-day intervention with phthalate free personal care products resulted in a 27.4% reduction in DEP metabolite (mono-ethyl phthalate) levels.

If phthalate exposures are ultimately found to be associated with body composition changes in young adults, it could be possible to decrease the risk of these body composition changes by modifying food selection, preparation and storage techniques, and changing use of personal care products in addition to traditional diet and physical activity interventions. This, in turn, could have significant impacts on obesity and chronic disease risk in the US.

While a few studies have indicated that dietary modification and changes in personal care products use can individually lower urinary phthalate levels, this study will be the first to combine both a dietary and personal care product intervention. In a study of 20 individuals, a 3-day dietary intervention of "fresh foods" (no canned food or foods wrapped in plastic) resulted in an average reduction in DEHP metabolites of 53-56%. Similarly, a study of 100 Latina girls found that a 3-day intervention with phthalate free personal care products resulted in a 27.4% reduction in DEP metabolite (mono-ethyl phthalate) levels. The hypothesis of this study is that an intervention that addresses both dietary and personal care product phthalate exposures can result in an even greater decrease in urinary phthalate metabolites.

Being tested
endocrine disruptor chemical reduction intervention
Medical subject headings
Overweight, Obesity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • endocrine disruptor chemical reduction interventionBehavioural

    Participants will take part in a 4-week intervention consisting of a modified (shortened) version of the Diabetes Prevention Program diet and physical activity group education program, with instructions to reduce endocrine disruptor chemical exposure through changes in food handling and personal care products.

Study groups in NCT03478345
Study groupRoleWhat they receive
THRIVE StudyExperimentalNot described
Receives: Behavioral: endocrine disruptor chemical reduction intervention

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Changes in urinary endocrine disrupting chemical levels (especially phthalates)

    Difference between urinary endocrine disrupting chemical levels from urine collected at the baseline study visit and urine collected at the final study visit.

    Measured: Six weeks

  2. Changes in body composition (weight and visceral adipose tissue volume)

    Difference between body weight and visceral adipose tissue volume (measured by dual x-ray absorptiometry) from baseline to final study visit.

    Measured: Six weeks

Secondary outcomes (1)
  1. Correlation between dietary patterns and urinary endocrine disrupting chemical levels

    Participants will complete three-day food records and urine specimen collections between the baseline study visit and the first group education session. Statistical testing (factor analysis) will be used to determine dietary patterns (e.g. diets high in processed foods or high in fat) that are associated with higher levels of urinary endocrine disrupting chemicals.

    Measured: baseline

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Mar 2018
  2. Study start13 Mar 2018
  3. Primary completion31 Dec 2018
  4. Study completion31 Dec 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
13 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03478345
Sponsor's protocol ID
111739
Acronym
THRIVE
Status last verified
Feb 2019
First submitted
20 Mar 2018
Last updated
15 Feb 2019
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Will not share data until study is complete and all data deidentified

Questions about this trial

What is this clinical trial studying?

A study testing endocrine disruptor chemical reduction intervention in people with Overweight, Obesity and Other Hyperalimentation, run by George Washington University at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 15 Feb 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Changes in urinary endocrine disrupting chemical levels (especially phthalates) (time frame: Six weeks). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Feb 2019.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in